GW823093C For The Treatment Of Type 2 Diabetes Mellitus

GlaxoSmithKline (GSK)

Status and phase: Terminated; Phase 2

Conditions: Diabetes Mellitus, Type 2

Treatments: Drug: GW823093C B; Drug: GW823093C A; Drug: GW823093C C

Study type: Interventional

Funder types: Industry

Identifiers

NCT00370942

DPB106652

Details and patient eligibility

About

This study was designed to find dose response and as extension in treatment of GW823093C.

Enrollment: 159 patients

Sex: All

Ages: 20 to 74 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Type 2 diabetes mellitus.
• Managed by diet therapy or receiving treatment with oral anti-diabetic monotherapy (excluding TZD (Thiazolidinediones))

Exclusion criteria

• Patients who have metabolic disease judged by investigator as a clinically significance
• Serious cardiovascular disease or serious hepatic disease

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

159 participants in 3 patient groups, including a placebo group

GW823093C A

Placebo Comparator group

Description:

A=45 mg

Treatment:

Drug: GW823093C A

GW823093C B

Placebo Comparator group

Description:

B=30 mg

Treatment:

Drug: GW823093C B

GW823093C C

Placebo Comparator group

Description:

C=15 mg

Treatment:

Drug: GW823093C C